InsidersTradesSigma
Follow the REGENXBIO Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, REGENXBIO Inc. has logged 131 public disclosures. Market capitalisation: €637.7m. The latest transaction was disclosed on 3 September 2026 (Retenue fiscale). Among the most active insiders: Mills Kenneth T.. Every trade is accessible without an account.
131
Insider Decl.
n/a
Thresholds
€813,740
2 ops.
Buy Volume
€5m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate REGENXBIO Inc. Buy (bullish), based on 11 analysts. Average price target: US$23.73.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,128 of 29,063 companies
28.4
score / 100
Value9
Quality48
FCF yld-20%
Earn yld-30%
EV/EBITDA·
ROE-138%
Gross mgn88%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations131 total
234 shares@ US$9.32Common StockSEC:0002062007-26-000005:0
4,902 shares@ US$9.32Common StockSEC:0001789335-26-000008:0
15,432 shares0Common StockSEC:0002023732-26-000008:0
49,196 shares@ US$9.14110.084% mcap47.3% of flowCommon StockSEC:0002023732-26-000008:1
Canonical exit: 24 Nov 2026 (T+90)
53,407 shares@ US$9.3560.094% mcap52.7% of flowCommon StockSEC:0002023732-26-000008:2
Canonical exit: 25 Nov 2026 (T+90)
4,699 shares@ US$9.690.0071% mcap7.0% of flowCommon StockSEC:0001521123-26-000008:0
7,468 shares@ US$9.690.011% mcap5.9% of flowCommon StockSEC:0001700659-26-000016:0
2,161 shares@ US$7.860.0022% mcap2.1% of flowCommon StockSEC:0001700659-26-000014:0
2,161 shares@ US$13.640.0039% mcap3.6% of flowCommon StockSEC:0001700659-26-000014:1
951 shares@ US$6.99551.0% of flowCommon StockSEC:0001346164-26-000006:0
1,453 shares@ US$10.180.0019% mcap2.3% of flowCommon StockSEC:0001346164-26-000006:1
6,818 shares@ US$13.090.012% mcap13.7% of flowCommon StockSEC:0001346164-26-000006:2
43,206 shares@ US$11.980.072% mcap100.0% of flowCommonSEC144:0001950047-26-006719
9,807 shares0Common StockSEC:0001872219-26-000001:0
5,124 shares@ US$10.354.5% of flowCommon StockSEC:0001700659-26-000008:0
5,267 shares@ US$11.164.9% of flowCommon StockSEC:0001700659-26-000006:0
4,700 shares@ US$11.168.3% of flowCommon StockSEC:0001521123-26-000006:0
225,000 shares@ US$13.0965.9% of flowCommon StockSEC:0001652824-26-000002:0
65,847 shares0Common StockSEC:0002062007-26-000003:0
73,749 shares0Common StockSEC:0001789335-26-000002:0
65,847 shares0Common StockSEC:0001700659-26-000004:0
73,749 shares0Common StockSEC:0001521123-26-000004:0
144,864 shares0Common StockSEC:0001346164-26-000004:0
1,238 shares@ US$14.4089.5% of flowCommon StockSEC:0002062007-26-000002:0
18,559 shares@ US$14.4019.7% of flowCommon StockSEC:0001346164-26-000002:0
25 of 131 declarations
关于 REGENXBIO Inc.
REGENXBIO Inc. 是一家在美国纳斯达克市场上市的美国生物技术公司，专注于体内基因治疗。公司总部位于马里兰州罗克维尔，致力于开发治疗严重遗传性和退行性疾病的疗法，特别侧重于罕见病和视网膜疾病。其核心竞争资产是专有的 NAV 技术平台，旨在支持基于 AAV 的基因递送和持久的治疗表达。REGENXBIO 成立于 2009 年，通过内部研发和战略性制药合作，已发展成为一家公认的基因治疗开发商。([ir.regenxbio.com](https://ir.regenxbio.com/?utm_source=openai)) 公司的管线集中于多个临床和商业前项目。最先进的资产是 RGX-202，一种用于杜氏肌营养不良症的基因疗法候选药物。2025 年和 2026 年，REGENXBIO 报告了令人鼓舞的中期数据，完成了关键性入组，并启动了商业生产活动，预计 2026 年第二季度初将获得关键性顶线数据，并计划于 2026 年年中提交 BLA 申请。在罕见溶酶体疾病方面，公司通过与 Nippon Shinyaku 的合作，正在开发用于 MPS II 的 RGX-121 和用于 MPS I 的 RGX-111。在眼科领域，REGENXBIO 正在与 AbbVie 合作推进 ABBV-RGX-314，用于湿性 AMD 和糖尿病视网膜病变。([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai)) 从商业角度来看，REGENXBIO 仍然主要是一家处于开发阶段的公司，但随着其主要项目接近潜在批准，其风险回报状况有所改善。其竞争定位建立在专有平台技术、集成制造能力以及针对高度未满足需求适应症的管线相结合的基础上。公司在其位于罗克维尔的制造创新中心生产 RGX-202，这加强了供应链控制，并可能支持未来的上市准备。([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai)) 从地理上看，REGENXBIO 仍然主要以美国为中心，总部、研究和制造业务均设在美国，而其合作伙伴关系则将潜在的商业化扩展到国际市场。与 AbbVie 和 Nippon Shinyaku 的协议扩大了公司的覆盖范围并验证了其技术平台。近期亮点包括 RGX-202 的持续积极数据、RGX-121 的持续监管进展以及与可能在 2026 年年中上市路径相关的制造规模扩大。对于欧洲投资者而言，这是一家具有高增长潜力的生物技术公司，但其成功仍然高度依赖于临床执行、监管决策和最终的市场采纳。([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-new-positive-interim-data-phase-iii-affinity/?utm_source=openai))
